1Mahoney RT, Krattiger A, Clemens JD, et al. The introduction of new vaccines into developing countries IV: Global Ac cess Strategies[J]. Vaccine, 2007, 25(20): 4003-4011.
2Watson DA, Musher DM. Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916[J]. Infect Immun, 19911, 58(9): 3135-3138.
3Wright A. Observations on propyhlactic inoculotion against pneu mococcus infections, and on the results which have been achioved byit[J]. Lancet, 1914, 1: 1-10,87-95.
4Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumoeoccal chellenge[J]. Vaccine, 2007,25 (16):2963-2973.
5O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaecharide vaccines: is hyporesponsiveness an issue? [J]. Lancet Infect Dis, 2007, 7 (9) : 597-6(16.
6Bisgard KM, Kao A, Leake J, et al. Haemophilus influenzae invasive disease in the United States. 1944-1995: near disap pea rance of a vaccine-preventable childhood disease [J]. Emerg Infect Dis, 1998,4(2) :229-237.
7Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adults [J]. Vaccine, 2007, 25(12): 2288 -2295.
8Whitney CG, Schaffner W, Butler JC. Rethinking recommendations for use of pneumococcal vaccines in adults[J]. Clin Infect Dis , 2001, 33(5) : 662-675.
9Riley ID, Lehmann DM, Alpers MP, et al. Pneumococcal vaccine prevents death from acute lower respiratory-tract infections in Papua NewGuinean children[J], Laneet, 1986, 2(8512) 877-881.
10Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children[J]. J Infect Dis, 1984, 149(6): 861-869.
10SYROGIANNOPOULOS GA, GRIVEA IN, DAVIES TA, et al. Antimierobial use and colonization with erythromycin - resistant streptococcus pneumomiae in Greece during the first 2 years of life [ J ]. Clin Infect Dis ,2003,31 (8) :887 - 893.
